Kanno Masafumi, Narita Norihiko, Fujimoto Yasushi, Wakisaka Naohiro, Yoshizaki Tomokazu, Kodaira Takeshi, Makita Chiyoko, Sato Yuichiro, Yamazaki Keisuke, Wakaoka Takanori, Shimode Yuzo, Tsuji Hiroyuki, Kito Ryosuke, Ishinaga Hajime, Hosokawa Seiji, Takakura Hiromasa, Nishimura Kunihiro, Matoba Takuma, Fujieda Shigeharu
Department of Otorhinolaryngology Head and Neck Surgery Graduate School of Medical Science University of Fukui, Fukui 910-1193, Japan.
Otorhinolaryngology/Cognitive and Speech Medicine Nagoya University Graduate School of Medicine, Nagoya University, Aichi 466-8550, Japan.
Cancers (Basel). 2019 Aug 15;11(8):1180. doi: 10.3390/cancers11081180.
The present study aimed to clarify the incidence and clinical outcomes of nasopharyngeal carcinoma (NPC) in the Chubu region of Japan from 2006 to 2015, compared with previous reports. A retrospective analysis was conducted based on medical records from 40 hospitals located in the Chubu region in the central Japanese main island, with a population of around 22.66 million individuals. This study was designed in line with to two previous clinical studies into NPC conducted in the same area of Japan. We recruited NPC patients diagnosed in hospitals across this area over a 10-year period (2006-2015) using a questionnaire about sex, age, primary site, clinical symptoms, pathology, Union for International Cancer Control (UICC) staging, serological exam, treatment, and survival. A total of 620 NPC patients were identified. The age-standardized incidence of NPC from 2006 to 2015 was 0.27 per 100,000 individuals per year. There were no significant differences between this study and the previous two studies conducted in the same area of Japan. The five-year overall survival rate for all patients was 75.9%, while those for patients with stages I, II, III, and IVA were 97%, 91%, 79%, and 68%, respectively. The age-standardized annual incidence of NPC in the present study was 0.27 per 100,000 individuals per year, which was relatively low and stable. The five-year overall survival rate for all NPC patients was significantly improved in this decade compared with previous studies. The smoking rates in male and female NPC patients were 64.5% and 18.8%, respectively, thereby suggesting the involvement of smoking in the incidence of NPC.
本研究旨在阐明2006年至2015年日本中部地区鼻咽癌（NPC）的发病率及临床结局，并与既往报告进行比较。基于位于日本本州岛中部中部地区的40家医院的病历进行回顾性分析，该地区人口约2266万。本研究是按照之前在日本同一地区进行的两项关于NPC的临床研究设计的。我们使用一份关于性别、年龄、原发部位、临床症状、病理、国际癌症控制联盟（UICC）分期、血清学检查、治疗和生存情况的问卷，招募了该地区10年间（2006 - 2015年）在各医院确诊的NPC患者。共识别出620例NPC患者。2006年至2015年NPC的年龄标准化发病率为每年每10万人0.27例。本研究与之前在日本同一地区进行的两项研究之间无显著差异。所有患者的五年总生存率为75.9%，而I期、II期、III期和IVA期患者的五年总生存率分别为97%、91%、79%和68%。本研究中NPC的年龄标准化年发病率为每年每10万人0.27例，相对较低且稳定。与之前的研究相比，这十年间所有NPC患者的五年总生存率有显著提高。男性和女性NPC患者的吸烟率分别为64.5%和18.8%，这表明吸烟与NPC的发病有关。
